Ricardo Serafim @ramserafim.bsky.social · 09/09/2026Looking forward to presenting our MPS1 covalent inhibitor story at #DDCEurope drugdiscoverychemistry.com/europe @iqsbarcelona.bsky.social 000
Ricardo Serafim @ramserafim.bsky.social · 17/10/2025The first picture with these highly motivated students who trusted on me to be their master’s (co)supervisor at IQS-Barcelona. We are working on exciting MedChem projects involving degraders and covalent inhibitors for underexplored protein kinases. Nice stories will come! Thank you very much, guys! 000
Ricardo Serafim @ramserafim.bsky.social · 25/08/2025Looking forward to receiving your manuscript!!! 000
Ricardo Serafim @ramserafim.bsky.social · 24/07/2025CALL FOR PAPERS💊🚨 SI about #CovalentModulators in the #ArchivderPharmazie (IF: 3.6) is open for submission! 🤩 I (IQS Barcelona) am happy to share as guest editor with Chiara Borsari (Milan Uni), Matthias Gehringer & Frank Boeckler (both from Tübingen Uni). onlinelibrary.wiley.com/page/journal...onlinelibrary.wiley.comArchiv der Pharmazie Call for Papers Covalent Modulators: A Multifaceted Approach in Medicinal Chemistry and Chemical Biology 000
Ricardo Serafim @ramserafim.bsky.social · 18/07/2025Gehringer and I have compiled and critically analysed High-Quality in vivo Chemical Probes for Protein Kinases available in the @chemicalprobes.org in 2024. Check it out and enjoy the reading! 😉 pubs.acs.org/doi/10.1021/...pubs.acs.orgHigh-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024Protein kinases are highly relevant drug targets, yet a significant fraction of the human kinome remains underexplored. Highly potent and selective small-molecule inhibitors used as chemical probes are invaluable tools for enabling the validation and translation of new kinase targets. This review provides an overview and analysis of the high-quality in vivo chemical probes for protein kinases published and deposited at the Chemical Probes Portal in the year 2024. We discuss the design strategies, molecular mechanism of action, details of their use in vitro and in vivo, as well as their application in target (in)validation. We also highlight the importance of wisely selecting chemical probes and encourage best practices in using such tool compounds. 000
Ricardo Serafim @ramserafim.bsky.social · 03/06/2025Na próxima semana estarei visitando virtualmente a Faculdade de Farmácia da Universidade Federal de Juiz de Fora para falar um pouco sobre minha trajetória acadêmica, ciência e química medicinal. O seminário será terça-feira 10 de Junho às 16:00 (horário de Brasília). 000
Ricardo Serafim @ramserafim.bsky.social · 16/04/2025We reported a reproducible decigram-scale protocol for accessing [1-(Ethoxycarbonyl)cyclopropyl] triphenylphosphonium tetrafluoroborate, a key reagent for exploration of MPS1 covalent inhibitors and many scaffolds with MedChem applications. chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...chemistry-europe.onlinelibrary.wiley.comGo for Gold: Development of a Scalable Synthesis of [1‐(Ethoxycarbonyl)cyclopropyl] Triphenylphosphonium Tetrafluoroborate, a Key Reagent to Explore Covalent Monopolar Spindle 1 Inhibitors[1-(Ethoxycarbonyl)cyclopropyl] triphenylphosphonium tetrafluoroborate is a limiting key reagent for synthesis of the tricyclic 5,6-dihydropyrimido[5,4-e]indolizine and related scaffolds, which are c... 000
Ricardo Serafim @ramserafim.bsky.social · 02/04/2025I'm delighted to be announced at the #FiMC as an Associate Editor of the renowned journal “Archiv der Pharmazie – Chemistry in Life Sciences” from the German Pharmaceutical Society. It is a pleasure to see my name among these brilliant and inspiring researchers from different parts of the world. 000
Ricardo Serafim @ramserafim.bsky.social · 29/03/2025We have officially started!!! The first reaction from the Serafim Group at the IQS-Barcelona, GQF (Grupo de Química Farmacéutica) 000
Ricardo Serafim @ramserafim.bsky.social · 28/02/2025Next week, here at the IQS-Barcelona, I will give my inaugural conference as Assistant Professor of Medicinal Chemistry. Looking forward to sharing some of my research contributions in the field of kinase inhibitors. 000
Reposted by Ricardo SerafimStructural Genomics Consortium (SGC) @thesgc.bsky.social · 06/01/2025Are you using the Chemical Probes Portal? If not, it’s time to explore this FREE resource which offers expert advice on >800 chemical probes, along with detailed guidelines on: ✅ How to choose the best probe for your protein of interest. ✅ How to use it appropriately to ensure reliable results.academic.oup.comThe Chemical Probes Portal – 2024: update on this public resource to support best-practice selection and use of small molecules in biomedical researchAbstract. The Chemical Probes Portal (www.chemicalprobes.org) is a free, public resource, based on expert-reviews, that supports the assessment, selection 053
Reposted by Ricardo SerafimNature @nature.com · 31/01/2025On Thursday, the US Food and Drug Administration approved suzetrigine for short-term pain management, making it the first non-opioid pain drug given a regulatory nod in more than 20 years. go.nature.com/40SKITtgo.nature.comUS drug agency approves potent painkiller — the first non-opioid in decadesThe FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels. 110124
Ricardo Serafim @ramserafim.bsky.social · 30/01/2025Many great talks at the 1st RQO-SCQ @scq.iec.cat 011
Reposted by Ricardo SerafimChemical Probes Portal @chemicalprobes.org · 28/01/2025🔬 Calling all PhD students & postdocs in chemistry/biology! Join us at the Chemical Probes Hackathon 🧪: 🗓️ Feb 20, 2025 | 10:00–14:30 📍 Vienna, Austria 💡 Evaluate chemical probes w/ experts & improve global science 🌍. 🎓 Earn a Certificate of Attendance! Learn more & register 👇 123
Reposted by Ricardo SerafimNature @nature.com · 21/01/2025Science is littered with serendipitous findings. Now, a study has put a figure on just how often chance findings happen. go.nature.com/3PHIMXsgo.nature.comHow often do unexpected scientific discoveries occur? More often that you might thinkA study assessed 1.2 million biomedical publications and measured the ‘unexpectedness’ of their findings. 210826